180 Life Sciences Corporate Media Kit

9 α7nAChR • Smoking cessation induced ulcerative colitis SCAs • Chronic pain • Early arthritis PLATFORM INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Fibrosis & Anti- TNF* • Dupuytren’s contracture • Frozen shoulder • POCD • NASH Est. start Q1 2023 Est. start Q3 2022 started Q2 2020 Est. start Q3 2021 Est. start Q4 2021 ongoing ongoing ongoing ongoing Three Platform Technologies Targeting Multiple Indications Est. start Q3 2021 *Regulatory approvals obtained from the MHRA and CCMO and the relevant accredited ethics committees to perform clinical trials in the UK and The Netherlands. No meetings have been held with, and no applications or requests for approval have been submitted to the FDA for any products at this time. 180 Life Sciences Corp. www.180lifesciences.com Q4 2020